SYNJ2 and prostate adenocarcinoma: For MSI, SYNJ2 expression was positively relevant to LUSC, sarcoma (SARC), and testicular germ cell tumors (TGCT) and negatively associated with MSI in BRCA, DLBC (lymphoid neoplasm diffuse large B-cell lymphoma), HNSCC and prostate adenocarcinoma (PRAD) (Fig. 9C).